RT Journal Article
SR Electronic
T1 Non-COVID-19 mortality in France, April 2020 - June 2022: reduction compared to pre-pandemic mortality patterns, relative increase during the Omicron period, and the importance of detecting SARS-CoV-2 infections
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.28.22282832
DO 10.1101/2022.11.28.22282832
A1 Edward Goldstein
YR 2022
UL http://medrxiv.org/content/early/2022/11/29/2022.11.28.22282832.abstract
AB Aims We compared the number of non-COVID-19 deaths between April 2020 and June 2022 to the expected number of deaths based on the patterns observed in the five years prior to the pandemic in France with the aims of (a) estimating the reduction in non-COVID-19 mortality, particularly due to reduction in the circulation of other respiratory viruses during the pandemic; (b) examining the degree to which SARS-CoV-2 infection was detected and characterized as a cause of death during different periods of the pandemic.Methods Using a previously developed regression model, we expressed weekly mortality rates in the 5-year period prior to the pandemic as a combination of influenza-associated mortality rates and baseline and a linear trend for the rates of non-influenza mortality. Estimates for the baseline and trend for non-influenza mortality together with estimates of influenza-related mortality prior to the pandemic were used to estimate expected mortality during the pandemic period.Results The number of recorded non-COVID-19 deaths between week 15, 2020 and week 26, 2022 in France was less than the expected number of deaths by 49,623 (95% CI (20364,78837)). Additionally, rates of non-COVID-19 mortality increased during the later part of the study period, with the difference between the number of non-COVID-19 deaths and the expected number of deaths during the last 52 weeks of the study period being greater than the corresponding difference for the first 52 weeks of the study period by 28,954 (24979,32918) deaths.Conclusions Our results suggest (a) the effectiveness of mitigation measures during the pandemic for reducing the rates of non-COVID-19 mortality, particularly mortality related to circulation of other respiratory viruses, including influenza (that was responsible for an annual average of 15,334 (12593,18077) deaths between 2015-2019 in France); (b) detection of a high proportion of SARS-CoV-2 infections leading to deaths in France, and characterization of those infections as the underlying cause of death. Additionally, while the increase in non-COVID-19 mortality during the later part of the study period is partly related to the temporal increase in the circulation of other respiratory viruses, there was an increase, particularly during the period of the circulation of the Omicron variant, in the proportion of hospitalizations with a SARS-CoV-2 infection in France that were coded as hospitalizations with COVID-19 (rather than COVID-19 hospitalizations), suggesting an increasing proportion of SARS-COV-2-associated deaths not being coded as COVID-19 deaths. All of this suggests the importance of timely detection of infections with SARS-CoV-2, particularly the Omicron variant (for which manifestations of disease complications are different compared to the earlier variants), and of providing the necessary treatment to patients to avoid progression to fatal outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study is based on de-identified, aggregate data available through refs. 6,14,15,16,17 https://covid19.who.int/ https://www.insee.fr/fr/statistiques/4931039?sommaire=4487854#tableau-figure1 https://www.insee.fr/fr/statistiques?debut=0&theme=1 https://www.sentiweb.fr/france/fr/?page=table https://app.powerbi.com/view?r=eyJrIjoiNjViM2Y4NjktMjJmMC00Y2NjLWFmOWQtODQ0NjZkNWM1YzNmIiwidCI6ImY2MTBjMGI3LWJkMjQtNGIzOS04MTBiLTNkYzI4MGFmYjU5MCIsImMiOjh9